Please assess the completion status of the following clinical trial:

Trial Title: Docetaxel and S-1 in Head and Neck Squamous Cell Carcinoma (HNSCC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* histologically confirmed HNSCC~* adequate primary site: oral cavity, oropharynx, hypopharynx, nasal cavity, paranasal sinus, other head and neck site (except nasopharynx)~* at least one measurable lesion~* no previous palliative chemotherapy (adjuvant/neoadjuvant chemotherapy and/or radiotherapy longer than 6 months ago is permitted)~* 18 years or older~* ECOG 0 or 1~* adequate laboratory result~* written, informed consent~Exclusion Criteria:~* pregnant or lactating women (negative pregnancy test within 7 days is required for women with potential of child-bearing)~* experimental drug clinical trial within 30 days~* other malignancy (exemption: treated basal cell carcinoma of skin, CIS, cured cancer with disease-free interval with more than 5 years)~* patient with organ transplantation~* grade 2 or more peripheral neuropathy~* grade 2 or more hearing loss~* severe, medical condition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): docetaxel+CDDP
- 2 (Type: EXPERIMENTAL): docetaxel+S-1

Based on this trial design, predict the completion outcome and termination type (if applicable).